0001104659-26-057100
SEC filingOperating loss widened to $14.9M as R&D spending increased, driving net loss of $13.7M compared to net income of $15.2M a year ago.
Corvus expects to continue incurring losses as it progresses soquelitinib through clinical development and toward potential commercialization. General and administrative expenses are anticipated to increase with headcount growth to support R&D and future commercialization efforts. The company's ability to raise additional capital on acceptable terms remains uncertain, and failure to do so could require significant reductions in operating expenses or delays in development programs.